VERISILICON
21.3.2024 01:01:30 CET | Business Wire | Press release
VeriSilicon (688521.SH) today announced the successful integration of its Display Processor IP DC8200 into StarFive’s JH-7110 RISC-V mass production SoC. With high performance, low power consumption and high security features, this collaboration delivers a complete intelligent vision processing platform solution tailored for diverse applications including cloud computing, industrial control, Network Attached Storage (NAS), tablets, and Human-Machine Interface (HMI).
VeriSilicon’s DC8200 IP supports advanced image quality enhancements, enabling user premium visual experiences. It can be configured to provide optimal solutions for target applications. By integrating VeriSilicon’s proprietary compression technology, DC8200 significantly reduces DDR bandwidth, thereby enhancing overall efficiency. Moreover, DC8200 supports dual operating systems and collaborates with the RISC-V CPU to meet diverse product requirements.
Additionally, DC8200 can form robust subsystems through seamless integration with VeriSilicon’s video/image processing IPs, delivering immersive experience to end users with crisp edge, fine detail enhancement, and rich color.
Thomas Xu, CEO of StarFive, said, “Our RISC-V based JH-7110 SoC performs a variety of complex video image processing and intelligent visual computing tasks, meeting the diverse real-time visual processing needs at the edge. VeriSilicon’s display processor IP offers high visual quality with low power consumption. We are committed to advancing innovation based on RISC-V technology. With companion pixel processing IP available through our IP partners, RISC-V based products can be brought to market at an accelerated pace.”
“Starfive’s JH-7110 is a leading RISC-V based intelligent vision processor equipped with advanced smart display capabilities. In the smart display domain, there exists a strong market demand for sophisticated image quality enhancement technologies,” said Wei-Jin Dai, Executive VP and GM of IP Division at VeriSilicon. “The Display Processor IP, as part of our extensive Glass-to-Glass (from camera-in to display-out) intelligent pixel processing IP portfolio, is engineered to deliver superior image quality while ensuring low power consumption. The integration of our DC8200 with JH-7110 is instrumental in driving the performance of numerous screens within the RISC-V ecosystem.”
About StarFive
Founded in 2018, StarFive is a Chinese local high-tech company with independent intellectual properties. As the leader of the RISC-V software and hardware ecosystem in China, StarFive provides world-leading products and solutions on RISC-V covering IP, SoC, development boards, etc.
StarFive has independently developed RISC-V CPU IPs and NoC IPs, of which Dubhe-90 is the max performance commercial RISC-V CPU IP in China, and StarLink-700 is the first mesh coherent interconnect fabric IP in China. Based on these core IPs, StarFive can also provide customers with RISC-V subsystem IP solutions for multi-core, big.little core, and manycore. These products can be applied in high-performance and energy-efficient scenarios, including industrial control, desktop computing, mobile, network communication, machine learning, artificial intelligence, and data centers. Meanwhile, StarFive has also delivered JH-7110 SoC, the world’s first high-performance RISC-V multimedia processor for mass-production. For more information, please visit https://www.starfivetech.com
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: http://www.verisilicon.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240319671767/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom